DOCU insider notice: 15,000 shares via Merrill Lynch valued at $1.2M
Rhea-AI Filing Summary
DocuSign (DOCU) Form 144 notice reports a proposed sale of 15,000 shares of common stock through Merrill Lynch, with an aggregate market value of $1,202,850 and an indicated outstanding share count of 201,104,117. The securities were originally acquired in 2008–2009 as initial venture capital funding from Sigma Partners in three lots totaling 15,000 shares. No securities were reported sold in the past three months. The filer affirms no undisclosed material adverse information and includes the standard signature and legal warnings.
Positive
- Sale size is immaterial relative to the stated 201,104,117 shares outstanding, suggesting limited market impact
- Acquisition history disclosed (dates and source: Sigma Partners, 2008–2009), supporting transparency
- No sales in past three months reported, indicating the filer has not recently been disposing material blocks
Negative
- Insider/affiliate sale is planned, which could be viewed negatively by some investors despite its small size
- Limited context on identity of the selling person and motivation for sale beyond standard representations
Insights
TL;DR Proposed sale is small relative to outstanding shares and appears routine for early investor liquidity.
The Form 144 shows an early investor (positions acquired in 2008–2009 from Sigma Partners) proposing to sell 15,000 shares via Merrill Lynch for roughly $1.2 million. Against the stated 201.1 million shares outstanding, this disposal represents a de minimis percentage of the float, suggesting limited market impact. The filing contains no disclosure of recent sales in the past three months and includes the standard attestation on material non-public information.
TL;DR The notice is a routine insider/affiliate sale filing; governance disclosure is standard and complete within form limits.
The document records acquisition origins tied to venture-capital initial funding and provides dates and unit counts for each lot. The broker and approximate sale date (09/15/2025) are listed, and the filer certifies compliance with public-disclosure statements. There is no indication of unusual arrangements or aggregated recent dispositions, which aligns with typical compliance for planned sales under Rule 144.